Shop Now Contact

Anti-Human IL-17A (Secukinumab Biosimilar)

Cat # Size Price Quantity
5056011 mg$175
5056025 mg$590
50560320 mg$1390

  Bulk/Custom

Product Details

CloneSecukinumab
ApplicationNeutralization, Intracellular Flow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionSecukinumab Biosimilar, Human IL17A Monoclonal Antibody
IsotypeHuman IgG1
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman IL17A
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Min Sample Size1 mg
Storage Conditions4ºC
Maximal Shelf Life12 months
Target NameIL-17A
Research AreasCytokines, Th17 cells
See All FormatsClone Secukinumab

Background Information

Secukinumab is a fully human monoclonal antibody belonging to the immunoglobulin G1 kappa (IgG1κ) subclass, developed to selectively target and neutralize interleukin-17A (IL-17A), a proinflammatory cytokine involved in the regulation of immune responses. Structurally, Secukinumab is a glycoprotein with a molecular weight of approximately 151 kilodaltons (kDa). The molecule consists of two identical heavy chains and two identical light chains linked by interchain disulfide bonds, forming the characteristic Y-shaped immunoglobulin architecture. Each heavy chain comprises a variable (VH) domain and three constant (CH1-CH3) domains, while each light chain contains a variable (VL) and a constant (CL) domain. The antibody is produced using recombinant DNA technology in mammalian cell systems, typically Chinese Hamster Ovary (CHO) cells, to preserve correct folding, glycosylation, and biological activity.

The antigen-binding (Fab) regions of Secukinumab contain complementarity-determining regions (CDRs) that define its high-affinity recognition sites for IL-17A. These CDRs interact non-covalently with specific epitopes on the IL-17A homodimer or IL-17A/IL-17F heterodimer, forming a stable immune complex that prevents IL-17A from binding to its receptor (IL-17RA/IL-17RC) on target cells. By sequestering IL-17A, Secukinumab impedes receptor-mediated signaling cascades such as NF-κB and MAPK pathways, which in turn modulate the expression of cytokines, chemokines, and antimicrobial peptides in experimental systems investigating immune pathway regulation.

The Fc (fragment crystallizable) region of Secukinumab, characteristic of IgG1 molecules, provides structural stability and contributes to its long serum half-life through recycling by neonatal Fc receptors (FcRn). This region, however, displays limited effector activity since Secukinumab’s primary mode of action involves cytokine neutralization rather than immune cell recruitment.

Data Sheets

Anti-Human IL-17A (Secukinumab Biosimilar) TDS

Related Products

Anti-Human CD4 Antibody, Clone 004AB

iF488 Anti-Human CD4 Antibody, Clone OKT4-Rec

iF647 Anti-Human CD4 Antibody, Clone OKT4-Rec

PE Anti-Human CD4 Antibody, Clone RPA-T4

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.